{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:25:16Z","timestamp":1792182316126,"version":"4.4.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1124\/mol.119.118646","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T21:45:16Z","timestamp":1582667116000},"page":"314-323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Obeticholic Acid Ameliorates Valproic Acid\u2013Induced Hepatic Steatosis and Oxidative Stress"],"prefix":"10.1016","volume":"97","author":[{"given":"Zhibo","family":"Gai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelin","family":"Krajnc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia L.","family":"Samodelov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd A.","family":"Kullak-Ublick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.119.118646_bib1","doi-asserted-by":"crossref","first-page":"36759","DOI":"10.1074\/jbc.M110.166231","article-title":"The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt\/beta-catenin pathways","volume":"285","author":"Abdelkarim","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.119.118646_bib2","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.bcp.2009.10.011","article-title":"Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis","volume":"79","author":"Aires","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/mol.119.118646_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0098-2997(03)00012-8","article-title":"Fate of 4-hydroxynonenal in vivo: disposition and metabolic pathways","volume":"24","author":"Alary","year":"2003","journal-title":"Mol Aspects Med"},{"key":"10.1124\/mol.119.118646_bib4","first-page":"5","article-title":"Recent advances in the development of farnesoid X receptor agonists","volume":"3","author":"Ali","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1124\/mol.119.118646_bib5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3109\/15376516.2010.497977","article-title":"Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients","volume":"20","author":"Amini-Shirazi","year":"2010","journal-title":"Toxicol Mech Methods"},{"key":"10.1124\/mol.119.118646_bib6","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1172\/JCI119839","article-title":"Troglitazone action is independent of adipose tissue","volume":"100","author":"Burant","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1124\/mol.119.118646_bib7","doi-asserted-by":"crossref","first-page":"11203","DOI":"10.1038\/s41598-017-11549-7","article-title":"Long-term administration of nuclear bile acid receptor FXR agonist prevents spontaneous hepatocarcinogenesis in Abcb4-\/- mice","volume":"7","author":"Cariello","year":"2017","journal-title":"Sci Rep"},{"key":"10.1124\/mol.119.118646_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9576503","article-title":"Study of valproic acid-enhanced hepatocyte steatosis","volume":"2016","author":"Chang","year":"2016","journal-title":"BioMed Res Int"},{"key":"10.1124\/mol.119.118646_bib9","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/03602530600959433","article-title":"Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity","volume":"38","author":"Chang","year":"2006","journal-title":"Drug Metab Rev"},{"key":"10.1124\/mol.119.118646_bib10","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI11245","article-title":"Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones","volume":"106","author":"Chao","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1124\/mol.119.118646_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/00498250802613620","article-title":"Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells","volume":"39","author":"Choi","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1124\/mol.119.118646_bib12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0006-2952(90)90560-8","article-title":"Early changes in hepatic redox homeostasis following treatment with a single dose of valproic acid","volume":"40","author":"Cotariu","year":"1990","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/mol.119.118646_bib13","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/clinchem\/34.5.890","article-title":"Valproic acid and the liver","volume":"34","author":"Cotariu","year":"1988","journal-title":"Clin Chem"},{"key":"10.1124\/mol.119.118646_bib14","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/jpet.105.084905","article-title":"A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis","volume":"314","author":"Fiorucci","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/mol.119.118646_bib15","doi-asserted-by":"crossref","first-page":"9815","DOI":"10.1038\/s41598-017-10168-6","article-title":"Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage","volume":"7","author":"Gai","year":"2017","journal-title":"Sci Rep"},{"key":"10.1124\/mol.119.118646_bib16","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1124\/mol.117.111047","article-title":"Effects of farnesoid X receptor activation on arachidonic acid metabolism, NF-kB signaling, and hepatic inflammation","volume":"94","author":"Gai","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.119.118646_bib17","doi-asserted-by":"crossref","first-page":"34268","DOI":"10.1074\/jbc.M300043200","article-title":"Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass","volume":"278","author":"Gavrilova","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.119.118646_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.gdata.2015.07.026","article-title":"Genome-wide profiling to analyze the effects of FXR activation on mouse renal proximal tubular cells","volume":"6","author":"Gui","year":"2015","journal-title":"Genom Data"},{"key":"10.1124\/mol.119.118646_bib19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1124\/mol.119.118646_bib20","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1212\/WNL.34.10.1393","article-title":"Selenium, zinc, and copper changes with valproic acid: possible relation to drug side effects","volume":"34","author":"Hurd","year":"1984","journal-title":"Neurology"},{"key":"10.1124\/mol.119.118646_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molmet.2018.01.005","article-title":"Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR","volume":"9","author":"Jadhav","year":"2018","journal-title":"Mol Metab"},{"key":"10.1124\/mol.119.118646_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000469338","article-title":"Functional heterogeneity of periportal and perivenous hepatocytes","volume":"35","author":"Jungermann","year":"1986","journal-title":"Enzyme"},{"key":"10.1124\/mol.119.118646_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fphys.2014.00285","article-title":"Reactive oxygen species and redox compartmentalization","volume":"5","author":"Kaludercic","year":"2014","journal-title":"Front Physiol"},{"key":"10.1124\/mol.119.118646_bib24","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/hep.1840040609","article-title":"The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies","volume":"4","author":"Kesterson","year":"1984","journal-title":"Hepatology"},{"key":"10.1124\/mol.119.118646_bib25","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/carcin\/bgl249","article-title":"Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice","volume":"28","author":"Kim","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1124\/mol.119.118646_bib26","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1124\/jpet.107.131185","article-title":"Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores","volume":"324","author":"Knapp","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/mol.119.118646_bib27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jhep.2007.07.027","article-title":"Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans","volume":"48","author":"Kovacs","year":"2008","journal-title":"J Hepatol"},{"key":"10.1124\/mol.119.118646_bib28","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"10.1124\/mol.119.118646_bib29","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","article-title":"Drug-induced liver injury: recent advances in diagnosis and risk assessment","volume":"66","author":"Kullak-Ublick","year":"2017","journal-title":"Gut"},{"key":"10.1124\/mol.119.118646_bib30","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1210\/me.2010-0117","article-title":"Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity","volume":"24","author":"Lee","year":"2010","journal-title":"Mol Endocrinol"},{"key":"10.1124\/mol.119.118646_bib31","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1210\/me.2011-1383","article-title":"Hepatocarcinogenesis in FXR-\/- mice mimics human HCC progression that operates through HNF1\u03b1 regulation of FXR expression","volume":"26","author":"Liu","year":"2012","journal-title":"Mol Endocrinol"},{"key":"10.1124\/mol.119.118646_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cbi.2014.03.014","article-title":"The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice","volume":"217","author":"L\u00edvero","year":"2014","journal-title":"Chem Biol Interact"},{"key":"10.1124\/mol.119.118646_bib33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0920-1211(93)90092-L","article-title":"Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. II. Influence of phenobarbital comedication","volume":"15","author":"L\u00f6scher","year":"1993","journal-title":"Epilepsy Res"},{"key":"10.1124\/mol.119.118646_bib34","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1038\/srep08114","article-title":"FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach","volume":"5","author":"Lu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1124\/mol.119.118646_bib35","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.20074","article-title":"Valproate therapy and nonalcoholic fatty liver disease","volume":"55","author":"Luef","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1124\/mol.119.118646_bib36","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1210\/me.2007-0025","article-title":"A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression","volume":"21","author":"Marzolini","year":"2007","journal-title":"Mol Endocrinol"},{"key":"10.1124\/mol.119.118646_bib37","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI200317223","article-title":"Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes","volume":"111","author":"Matsusue","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1124\/mol.119.118646_bib38","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1210\/endo.141.11.7771","volume":"141","author":"Memon","year":"2000","journal-title":"Endocrinology"},{"key":"10.1124\/mol.119.118646_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tem.2017.11.002","article-title":"Role of bile acids in metabolic control","volume":"29","author":"Molinaro","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"10.1124\/mol.119.118646_bib40","doi-asserted-by":"crossref","first-page":"E1020","DOI":"10.3390\/ijms17071020","article-title":"Computational identification of the paralogs and orthologs of human cytochrome P450 superfamily and the implication in drug discovery","volume":"17","author":"Pan","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1124\/mol.119.118646_bib41","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J Med Chem"},{"key":"10.1124\/mol.119.118646_bib42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00011-010-0306-1","article-title":"SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-\u03b3 by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts","volume":"60","author":"Renga","year":"2011","journal-title":"Inflamm Res"},{"key":"10.1124\/mol.119.118646_bib43","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0022-3565(24)37076-4","article-title":"Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid","volume":"283","author":"Sadeque","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/mol.119.118646_bib44","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1600-0773.1999.tb02025.x","article-title":"Effect of acute and chronic administration of sodium valproate on lipid peroxidation and antioxidant system in rat liver","volume":"85","author":"Se\u00e7kin","year":"1999","journal-title":"Pharmacol Toxicol"},{"key":"10.1124\/mol.119.118646_bib45","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1021\/acsmedchemlett.8b00423","article-title":"Novel isoxazole derivatives with potent FXR agonistic activity prevent acetaminophen-induced liver injury","volume":"10","author":"Sepe","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/mol.119.118646_bib46","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1528-1157.1993.tb02419.x","article-title":"Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity","volume":"34","author":"Siemes","year":"1993","journal-title":"Epilepsia"},{"key":"10.1124\/mol.119.118646_bib47","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"10.1124\/mol.119.118646_bib48","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1038\/cddis.2012.99","article-title":"PPAR\u03b3 isoforms differentially regulate metabolic networks to mediate mouse prostatic epithelial differentiation","volume":"3","author":"Strand","year":"2012","journal-title":"Cell Death Dis"},{"key":"10.1124\/mol.119.118646_bib49","doi-asserted-by":"crossref","first-page":"G1245","DOI":"10.1152\/ajpgi.00439.2011","article-title":"Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma","volume":"303","author":"Su","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/mol.119.118646_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086795","article-title":"Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices","volume":"9","author":"Szalowska","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/mol.119.118646_bib51","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1021\/tx9801864","article-title":"Assessing the mechanism of metabolism-dependent valproic acid-induced in vitro cytotoxicity","volume":"12","author":"Tabatabaei","year":"1999","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/mol.119.118646_bib52","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0090-9556(25)07371-4","article-title":"Conjugation of glutathione with a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, catalyzed by rat hepatic glutathione-S-transferases","volume":"24","author":"Tang","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/mol.119.118646_bib53","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1021\/tx00047a006","article-title":"Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status","volume":"8","author":"Tang","year":"1995","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/mol.119.118646_bib54","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0891-5849(03)00151-5","article-title":"The effect of valproic acid on hepatic and plasma levels of 15-F2t-isoprostane in rats","volume":"34","author":"Tong","year":"2003","journal-title":"Free Radic Biol Med"},{"key":"10.1124\/mol.119.118646_bib55","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/toxsci\/kfi184","article-title":"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats","volume":"86","author":"Tong","year":"2005","journal-title":"Toxicol Sci"},{"key":"10.1124\/mol.119.118646_bib56","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/toxsci\/kfi185","article-title":"Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes","volume":"86","author":"Tong","year":"2005","journal-title":"Toxicol Sci"},{"key":"10.1124\/mol.119.118646_bib57","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1053\/j.gastro.2007.05.015","article-title":"Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy","volume":"133","author":"Van Mil","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1124\/mol.119.118646_bib58","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00431-009-0927-y","article-title":"Nonalcoholic fatty liver disease during valproate therapy","volume":"168","author":"Verrotti","year":"2009","journal-title":"Eur J Pediatr"},{"key":"10.1124\/mol.119.118646_bib59","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1172\/JCI118703","article-title":"Regulation of PPAR gamma gene expression by nutrition and obesity in rodents","volume":"97","author":"Vidal-Puig","year":"1996","journal-title":"J Clin Invest"},{"issue":"4 Pt B","key":"10.1124\/mol.119.118646_bib60","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbadis.2017.08.033","article-title":"Drug-induced bile duct injury","volume":"1864","author":"Visentin","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1124\/mol.119.118646_bib61","first-page":"1573","article-title":"Mechanisms of amiodarone and valproic acid induced liver steatosis in mouse in vivo act as a template for other hepatotoxicity models","volume":"88","author":"Vitins","year":"2014","journal-title":"Arch Toxicol"},{"key":"10.1124\/mol.119.118646_bib62","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0140-6736(80)92543-X","article-title":"Acute liver disease associated with sodium valproate","volume":"2","author":"Ware","year":"1980","journal-title":"Lancet"},{"key":"10.1124\/mol.119.118646_bib63","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/CIRCRESAHA.109.206334","article-title":"Hypoxia triggers subcellular compartmental redox signaling in vascular smooth muscle cells","volume":"106","author":"Waypa","year":"2010","journal-title":"Circ Res"},{"key":"10.1124\/mol.119.118646_bib64","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3389\/fphar.2019.00819","article-title":"Lipidomic profiling reveals disruption of lipid metabolism in valproic acid-induced hepatotoxicity","volume":"10","author":"Xu","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1124\/mol.119.118646_bib65","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","article-title":"Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res"},{"key":"10.1124\/mol.119.118646_bib66","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/aps.2013.135","article-title":"Combined effects of a high-fat diet and chronic valproic acid treatment on hepatic steatosis and hepatotoxicity in rats","volume":"35","author":"Zhang","year":"2014","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/mol.119.118646_bib67","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis","volume":"51","author":"Zhang","year":"2009","journal-title":"J Hepatol"},{"key":"10.1124\/mol.119.118646_bib68","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/acer.13049","article-title":"Hepatic peroxisome proliferator-activated receptor gamma signaling contributes to alcohol-induced hepatic steatosis and inflammation in mice","volume":"40","author":"Zhang","year":"2016","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1124\/mol.119.118646_bib69","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/hep.1840020513","article-title":"Valproate-induced hepatic injury: analyses of 23 fatal cases","volume":"2","author":"Zimmerman","year":"1982","journal-title":"Hepatology"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24010101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24010101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.119.118646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:33:16Z","timestamp":1739961196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24010101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0026895X24010101"],"URL":"https:\/\/doi.org\/10.1124\/mol.119.118646","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obeticholic Acid Ameliorates Valproic Acid\u2013Induced Hepatic Steatosis and Oxidative Stress","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.119.118646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}